Methysergide is a semi-synthetic ergot alkaloid derivative with serotonergic activity. It has historically been used as a preventive medication for migraine and cluster headache, particularly in patients requiring specialized prophylactic treatment.
Methysergide and its active metabolite, methylergometrine, exert effects on several serotonin receptors and vascular smooth-muscle pathways. Its pharmacological activity is associated with modulation of serotonergic mechanisms involved in headache disorders.
Methysergide API is a specialized pharmaceutical active ingredient used for qualified pharmaceutical manufacturing, formulation development, analytical testing and research applications.
Methysergide produces pharmacological effects through interaction with serotonin receptors, particularly pathways associated with vascular and neuronal responses involved in migraine.
Its active metabolite, methylergometrine, contributes substantially to its pharmacological activity. The exact contribution of individual receptor subtypes to its clinical effects is complex.
Methysergide API is associated with:
Regulatory note: Methysergide has restricted or discontinued use in several markets because of safety concerns associated with prolonged treatment, including fibrotic complications. Its availability and approved indications therefore vary by country and regulatory jurisdiction.
| Parameter | Specification |
|---|---|
| Appearance | White crystalline powder or crystals |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 3.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 2.0% |
| Water Content | NMT 3.0% |
| Melting Point | Approximately 220–230 °C |